Company Registration No. 11142238 (England and Wales)
Valogen Biosciences Limited
Unaudited accounts
for the year ended 31 January 2025
Valogen Biosciences Limited
Unaudited accounts
Contents
Valogen Biosciences Limited
Statement of financial position
as at 31 January 2025
Tangible assets
13,413
16,842
Cash at bank and in hand
(12,320)
47,483
Creditors: amounts falling due within one year
(17,304)
(21,380)
Net current (liabilities)/assets
(20,229)
41,864
Net (liabilities)/assets
(6,816)
58,706
Called up share capital
11,773
11,561
Share premium
188,362
163,481
Profit and loss account
(206,951)
(116,336)
Shareholders' funds
(6,816)
58,706
For the year ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 18 April 2025 and were signed on its behalf by
Peter Elliott Luebcke
Director
Company Registration No. 11142238
Valogen Biosciences Limited
Notes to the Accounts
for the year ended 31 January 2025
Valogen Biosciences Limited is a private company, limited by shares, registered in England and Wales, registration number 11142238. The registered office is Upton Barton, South Milton, Kingsbridge, TQ7 3JF, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
20% Reducing Balance
Computer equipment
25% Straight Line
Government grants, including research and development expenditure credits (RDEC), are recognised when there is reasonable assurance that the company will comply with the conditions attached to the grant and the grant will be received. Grants are recognised in profit or loss as other income in the period in which the related qualifying expenditure is incurred or the performance conditions are met. Grants are measured at the fair value of the amount receivable.
Expenditure on research and development is written off in the year in which it is incurred.
The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are recognised in the profit and loss account when due.
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. A deferred tax asset is only recognised to the extent that it is probable that future taxable profits will be available against which the asset can be utilised.
Valogen Biosciences Limited
Notes to the Accounts
for the year ended 31 January 2025
4
Tangible fixed assets
Plant & machinery
Computer equipment
Total
Cost or valuation
At cost
At cost
At 1 February 2024
20,753
427
21,180
At 31 January 2025
20,753
427
21,180
At 1 February 2024
4,151
187
4,338
Charge for the year
3,322
107
3,429
At 31 January 2025
7,473
294
7,767
At 31 January 2025
13,280
133
13,413
At 31 January 2024
16,602
240
16,842
Amounts falling due within one year
6
Creditors: amounts falling due within one year
2025
2024
Taxes and social security
1,807
-
Other creditors
10,000
20,000
Loans from directors
-
542
7
Average number of employees
During the year the average number of employees was 3 (2024: 3).